Gómez et al., 2020 - Google Patents
Enhancement of HIV-1 env-specific CD8 T cell responses using interferon-stimulated gene 15 as an immune adjuvantGómez et al., 2020
View PDF- Document ID
- 11381557731087338023
- Author
- Gómez C
- Perdiguero B
- Falqui M
- Marín M
- Bécares M
- Sorzano C
- García-Arriaza J
- Esteban M
- Guerra S
- Publication year
- Publication venue
- Journal of virology
External Links
Snippet
Induction of the endogenous innate immune system by interferon (IFN) triggers the expression of many proteins that serve like alarm bells in the body, activating an immune response. After a viral infection, one of the genes activated by IFN induction is the IFN …
- 230000004044 response 0 title abstract description 65
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kalams et al. | Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults | |
| Johnson et al. | Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation | |
| Gómez et al. | Enhancement of HIV-1 env-specific CD8 T cell responses using interferon-stimulated gene 15 as an immune adjuvant | |
| Billeskov et al. | Low antigen dose in adjuvant-based vaccination selectively induces CD4 T cells with enhanced functional avidity and protective efficacy | |
| Cao et al. | Immunogenicity of a recombinant human immunodeficiency virus (HIV)–canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 vaccine study | |
| Katae et al. | Coadministration of an interleukin-12 gene and a Trypanosoma cruzi gene improves vaccine efficacy | |
| Mpendo et al. | A phase I double blind, placebo-controlled, randomized study of the safety and immunogenicity of electroporated HIV DNA with or without interleukin 12 in prime-boost combinations with an Ad35 HIV vaccine in healthy HIV-seronegative African adults | |
| Garber et al. | Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques | |
| Cao et al. | A single vaccine protects against SARS-CoV-2 and influenza virus in mice | |
| Grubor-Bauk et al. | Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs | |
| Ondondo et al. | Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice | |
| Zhong et al. | Type I interferon promotes humoral immunity in viral vector vaccination | |
| Ahmad et al. | Sm‐p80‐based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni | |
| Mahdavi et al. | Granulocyte‐macrophage colony‐stimulating factor, a potent adjuvant for polarization to Th‐17 pattern: an experience on HIV‐1 vaccine model | |
| Feng et al. | Induction of CD8+ T‐lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus | |
| Klasse et al. | Reappraising the value of HIV-1 vaccine correlates of protection analyses | |
| Perdiguero et al. | Heterologous combination of VSV-GP and NYVAC vectors expressing HIV-1 trimeric gp145 Env as vaccination strategy to induce balanced B and T cell immune responses | |
| US10052377B2 (en) | Cellular vaccine and method of inducing an immune response in a subject | |
| Strbo et al. | Gp96SIVIg immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa | |
| Daradoumis et al. | An endogenous retrovirus vaccine encoding an envelope with a mutated immunosuppressive domain in combination with anti-PD1 treatment eradicates established tumours in mice | |
| US20070048333A1 (en) | CD4+ T-lymphocyte-specific Hepatitis C virus-epitopes | |
| Bansal et al. | Enhanced recognition of HIV-1 cryptic epitopes restricted by HLA class I alleles associated with a favorable clinical outcome | |
| Oom et al. | The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response | |
| Lietz et al. | Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection | |
| Chea et al. | Novel modified vaccinia virus Ankara vector expressing anti-apoptotic gene B13R delays apoptosis and enhances humoral responses |